University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone

Simple item page
dc.contributor.authorPrice, David
dc.contributor.authorHenley, William
dc.contributor.authorDelfini Cançado, José Eduardo
dc.contributor.authorFabbri, Leonardo M
dc.contributor.authorKerstjens, Huib AM
dc.contributor.authorPapi, Alberto
dc.contributor.authorRoche, Nicolas
dc.contributor.authorŞen, Elif
dc.contributor.authorSingh, Dave
dc.contributor.authorVogelmeier, Claus
dc.contributor.authorBarille, Sara
dc.contributor.authorNudo, Elena
dc.contributor.authorCarter, Victoria
dc.contributor.authorSkinner, Derek
dc.contributor.authorVella, Rebecca
dc.contributor.authorGeorges, George
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2022-02-16T14:42:01Z
dc.date.available2022-02-16T14:42:01Z
dc.date.issued2022-02-15
dc.descriptionAcknowledgements Professor Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Jaco Vooriham is acknowledged for his contribution to protocol development. We would also like to acknowledge Ms. Shilpa Suresh (MSc) of the Observational and Pragmatic Research Institute (OPRI), Singapore, for editorial and formatting assistance which supported the development of this publication.en
dc.description.statusPeer revieweden
dc.format.extent16
dc.format.extent2542035
dc.identifier212224368
dc.identifier71cdea97-09f4-4be9-b5f4-3bdd94ad4e84
dc.identifier85125067641
dc.identifier.citationPrice, D, Henley, W, Delfini Cançado, J E, Fabbri, L M, Kerstjens, H AM, Papi, A, Roche, N, Şen, E, Singh, D, Vogelmeier, C, Barille, S, Nudo, E, Carter, V, Skinner, D, Vella, R & Georges, G 2022, 'Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone', International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 355—370. https://doi.org/10.2147/COPD.S342357en
dc.identifier.doi10.2147/COPD.S342357
dc.identifier.iss17en
dc.identifier.issn1176-9106
dc.identifier.urihttps://hdl.handle.net/2164/18073
dc.language.isoeng
dc.relation.ispartofInternational journal of chronic obstructive pulmonary diseaseen
dc.subjectInhaled corticosteroidsen
dc.subjectpneumoniaen
dc.subjectCOPDen
dc.subjectExtrafine beclometasoneen
dc.subjectfluticasoneen
dc.subjectR Medicineen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleInterclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasoneen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Price_etal_IJCOPD_INterclass_Difference_In_VoR.pdf
Size:
2.42 MB
Format:
Adobe Portable Document Format
Download

Collections

All research